Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
Collinson
P O
PO
Department of Chemical Pathology, Mayday University Hospital, Thornton Heath, Surrey, UK.
Hjelm
C J
CJ
Canepo-Anson
R
R
D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011345:Fenofibrate / Q000627:therapeutic use*; D058607:Fibric Acids; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods*
D058607:Fibric Acids; D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D002995:Clofibric Acid; C019304:ciprofibrate; D011345:Fenofibrate